LOS ANGELES--(EON: Enhanced Online News)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (Nasdaq: AGIO) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at email@example.com.
The investigation focuses on whether Agios and certain of its officers and/or directors violated federal securities laws. Agios revealed updated data for its AG-348 and AG-519 molecules, which are used to treat pyruvate kinase deficiency, at the 2016 American Society of Hematology meeting. A report stated Grade 2 thrombocytopenia, which reduces platelets in blood cells, was found in a patient receiving AG-519, and that an ongoing severe adverse event of drug-related cholestatic hepatitis was noted in a bioavailability and food effect study after a dose of 300 mg. When this news was released to the public, the value of Agios declined as much as 15.85% on December 5, 2016, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.